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Abstract 
The integrated use of dialysis modalities alongside transplantation over a life time of renal 
replacement is often necessary and well established. In general, outcomes are more favourable 
when using home-based treatments but what is less certain is the value of using these modalities 
sequentially. To explore this, using data from the Australian and New Zealand Dialysis and 
Transplantation Registry, patients using peritoneal dialysis (PD) followed by home haemodialysis 
(HHD) were compared using propensity matching to those treated by PD and HHD only. For 
combined patient and technique survival, or patient survival only, outcomes for those using 
integrated home therapies (PD followed by HHD) had similar outcomes to HHD alone, whereas those 
using PD only fared less well. The proportion of patients on PD transitioning to HHD was very small, 
as was the absolute number of patients using PD to HHD integrated pathway, so caution is needed in 
generalising these results to a wider patient population, but the concept of integrating home 
therapies in this way is supported by the findings. The study also points to a need for a better 
understanding of what happens at the transition between modalities so as to improve patient 
outcomes and experiences of dialysis care. 
 
 
The concept of integrating different renal replacement modalities is not new. For many patients 
dialysis is the bridge to or between kidney transplantation where it provides a welcome safety net 
and an integrated care model that incorporates peritoneal dialysis, (PD) and haemodialysis (HD) with 
transplantation is well established.(1,2)  In truth, younger patients with a lifetime of renal 
replacement in front of them will almost always require several modality switches over the years 
and there is some evidence that the use of more than one dialysis modality can confer benefits. PD 
has theoretical advantages as a preferred initial dialysis modality, such as the relative preservation 
of residual kidney function (3,4) or sites for vascular access(5) and cost-effectiveness,(6) supported 
by empirical evidence of a relative survival advantage compared to centre based haemodialysis 
during the first year or more of treatment and better overall survival in patients using more than one 
modality.(7–11) Nested within this generalisable integrated care approach is what has been termed 
the ‘Integrated Home Dialysis Model’, for example PD followed by home haemodialysis (HHD). 
However it is not known whether the early advantage of PD is still evident under these 
circumstances or whether it is even detrimental. Matched studies from the UK Renal Registry 
comparing the outcomes of patients starting with PD versus HHD have suggested that the latter is 
associated with better outcomes.(12,13) It is as an attempt to answer this question that Nadeau-
Fredette and colleagues have analysed data from the Australia and New Zealand Dialysis and 
Transplant (ANZDATA) registry, published in this edition of Nephrology Dialysis Transplantation.(14) 
They have also recently published an analysis of PD versus HHD as incident treatments from the 
same database.(15) 
Their approach is to compare the outcomes of three patient groups, those who had PD-only, HHD-
only, and those who transitioned from PD to HD, taking combined patient and home-dialysis 
technique survival as their primary endpoint (although patient survival alone was also analysed). This 
type of analysis throws up two major methodological problems – first, how to match these patient 
groups sufficiently well as to reduce case-mix bias and second, how to account for the fact that 
patients undergoing sequential therapies need to survive for a period on the first treatment before 
they can transition, so-called immortal time bias. Their approach to the first is to use propensity 
matching of baseline patient characteristics, so as to select from the larger group of incident PD 
patients those who are most like those starting on HHD or transitioning from PD to HHD. The second 
problem is dealt with by ensuring that patients from the single modality groups (in each case twice 
as many as in the PD to HD group) had to survive on their treatment at least as long as those 
patients who made the switch were on PD. The main finding was that integrated use of PD and HHD 
is associated with similar outcomes as HHD, suggesting that prior PD does not have a negative 
influence on subsequent HHD outcomes. Compared to those PD patients not switching to HHD (i.e. 
either remaining on PD or switching to centre HD) technique and patient survival was significantly 
better for those undergoing integrated home therapies, but for reasons that will be discussed 
further it cannot be concluded that routine application of the ‘home integrated pathway’, even if 
this were practicably possible, would necessarily lead to better outcomes overall. 
The ANZDATA group and co-authors are to be congratulated on undertaking this analysis, which very 
few, if any other national registries could have done, as it requires a relatively, large number of HHD 
patients, especially those who switched from PD, to be meaningful. Even so, it is important to 
recognise that the absolute number of patients included in the analysis is still small, representing 
between 0.7% and 1.4% of all patients treated with home dialysis during this period,  2000-2013, 
(there were only 93 patients treated by PD then HHD in the 13 years of study, 90% of which are 
included), already a selected group of the whole population undergoing renal replacement. Although 
their propensity matching was effective, as shown by the McFadden fit, score distribution and 
equivalency cross a wide range of baseline covariates, (which includes amongst other items 
comorbidity, smoking, BMI, late referral and indigenous race), the explanation as to why so few PD 
patients transition to HHD remains unanswered. The implication, however, is that HHD remains a 
highly selective treatment, being used as a primary modality in just 6% of new home dialysis patients 
and less than 1% of those who started on PD. This degree of selection, reflected in the excellent 
overall survival rates of these patients also seen in other registry analyses including 
ANZDATA,(12,15) likely results in a degree of confounding that even the most sophisticated baseline 
matching techniques will be unable to account for. However it is not just baseline confounding that 
is at question here; for those transitioning from PD to either HHD or centre-based HD there is a 
second selection hurdle. Ideally the authors would have undertaken second round of propensity 
matching at this time point that would have included information of much greater depth and 
richness with the objective of understanding why it was that such a small proportion of PD patients 
are felt or feel able to switch to HHD. This could be due to patient level factors such as progressive ill 
health, burn-out, lack of social support or dialysis centre level factors known to influence the uptake 
of home therapies, not least physician enthusiasm and expertise.(16) This is not a criticism of the 
present study as it is clear that this level of granularity is well beyond the scope of a registry analysis 
such as this, but is does point to the need for high quality research that focuses on the whole issue 
of modality transition, especially in view of the relatively poor outcomes observed in the PD-only 
group both for technique and patient survival. Indeed it provides further rationale, if it were needed, 
for the International Peritoneal Dialysis Outcomes and Practice Patterns Study, PDOPPS, which is 
now underway in the US, Canada, UK, Australia and Japan.(17) PDOPPS has taken technique failure 
as its primary endpoint, redefining the way its causes are captured, which can often be multiple, 
with the intention of establishing those practice patterns that prevent or delay technique failure 
without adversely affecting overall patient survival.(18)     
So what have we learned from this study? Proponents of home dialysis can advise their patients that 
there is further evidence for good outcomes when integrating home modalities – albeit in a small 
proportion of the dialysis population – and starting with PD and graduating to HHD appears to be a 
strategy that is supported by the evidence. For those who are not proponents, then this is still 
information that should be made available when discussing dialysis treatment options, for example 
when using a shared decision aid.(19) It also strongly suggests that we need as clinicians to make a 
better job of planning and managing modality transitions through regular discussions with our 
patients and on the basis of better quality evidence. For example, what defines a good or a bad 
transition? It is not just the optimisation patient or technique survival, although clearly these are 
key, but also the associated patient experience, morbidity and how best to convey the pros and cons 
of these treatment opportunities that we need to understand better so as to improve their lives on 
dialysis. 
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